Assenagon Asset Management S.A. Increases Stake in TG Therapeutics, Inc. $TGTX

by · The Markets Daily

Assenagon Asset Management S.A. lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) by 218.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 510,054 shares of the biopharmaceutical company’s stock after acquiring an additional 349,664 shares during the quarter. Assenagon Asset Management S.A.’s holdings in TG Therapeutics were worth $16,944,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TGTX. Danske Bank A S bought a new position in TG Therapeutics during the 3rd quarter valued at about $25,000. Optiver Holding B.V. lifted its stake in TG Therapeutics by 3,485.7% in the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 573 shares during the period. Finally, Truvestments Capital LLC boosted its position in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 1,026 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $55.83 on Friday. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. The company has a market capitalization of $8.55 billion, a P/E ratio of 19.52 and a beta of 1.68. The company’s 50-day simple moving average is $42.19 and its two-hundred day simple moving average is $34.57. TG Therapeutics, Inc. has a one year low of $25.28 and a one year high of $57.38.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.11). The company had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business’s revenue was up 69.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS. As a group, equities analysts anticipate that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the topic of several recent analyst reports. Jefferies Financial Group reiterated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of TG Therapeutics in a report on Wednesday, May 27th. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $58.60.

Check Out Our Latest Stock Analysis on TG Therapeutics

TG Therapeutics Profile

(Free Report)

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

Featured Articles

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report).